Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy. Our vision is the same throughout the clinical development process – bring new options to patients who may need them the most. References: M; LWR. Interleukin 12: Still a promising candidate for tumor immunotherapy?
98 
Let's personalize your content